• John L. Lubniewski

    President, Chief Executive Officer and Member of the Board of Directors
    Mr. Lubniewski has served as our President and Chief Executive Officer and as a member of our Board of Directors since April 2019 and previously served as our President and Chief Operating Officer since April 2018. Prior to this, he served as our Senior Vice President and Chief Business Officer since April 2011. Mr. Lubniewski joined us from Ventana Medical Systems, Inc. (“Ventana”), a medical diagnostics company and member of the Roche Group, and the global headquarters of Roche Tissue Diagnostics (“RTD”) where he served in leadership roles for nine years both before and after the acquisition of Ventana by Roche Holdings, Inc. (“Roche”) in March 2008. From August 2010 to April 2011, Mr. Lubniewski was Senior Vice President and Lifecycle Leader, Advanced Staining Platforms at Ventana. From January 2008 to August 2010, Mr. Lubniewski served as Senior Vice President and Lifecycle Leader, Clinical Assays at RTD, with responsibility for three lifecycle teams, technical marketing and medical marketing and global accountability for all RTD clinical assay products. Prior to the Roche acquisition of Ventana, Mr. Lubniewski served at Ventana as Senior Vice President, Advanced Staining Business Unit, Vice President Worldwide Marketing and Translational Diagnostic Business Unit, and General Manager, Research Products. In these roles, Mr. Lubniewski was responsible for a variety of assay and platform development and commercialization efforts. Prior to Ventana, Mr. Lubniewski worked for over ten years in a variety of divisional, sector and corporate leadership roles at Corning, Incorporated, a multinational technology company that specializes in specialty glass, ceramics and related materials and technologies including advanced optics, primarily for industrial and scientific applications. Mr. Lubniewski earned a B.S. in Chemical Engineering from Clarkson University. Our Board of Directors believes that Mr. Lubniewski’s extensive executive management experience in commercialization, marketing, strategic planning and management of operations, as well as his service as our Chief Executive Officer, qualify him to serve on our Board of Directors. 
    • Shaun D. McMeans

      Senior Vice President and Chief Financial Officer
      Mr. McMeans has served as our Chief Financial Officer since February 2012. He previously was our Vice President of Finance & Administration from February 2012 until February 2018. Prior to joining us, Mr. McMeans was Vice President – Finance of Securaplane Technologies, Inc., a product supply company and division of Meggitt PLC, an aerospace, defense and energy conglomerate, from May 2011 to February 2012. Mr. McMeans was a financial consultant from February 2008 to April 2011, working both in an individual capacity and as a partner for Tatum LLC, a consulting company. Prior to February 2008, Mr. McMeans was Chief Financial Officer for The Long Companies, a full service residential and commercial real estate division of Berkshire Hathaway, Inc. Mr. McMeans also worked for over five years at LXU Healthcare, Inc., a manufacturer and distributor of specialty surgical equipment, as Controller and then Chief Financial and Operating Officer. In his early career, Mr. McMeans worked in roles of increasing responsibility, including Director of Finance, for Burnham Holdings, Inc., formerly Burnham Corporation, a manufacturer and distributor of residential and commercial hydronic heating equipment. Mr. McMeans received his B.S. in Accounting from The Pennsylvania State University.
      • Byron T. Lawson

        Senior Vice President and Chief Commercial Officer
        Mr. Lawson has served as our Senior Vice President and Chief Commercial Officer since January 2020 and previously served as our Senior Vice President, Pharma Business Unit since January 2018. Prior to this, he served as our Vice President, Commercial Operations since April 2016 and Senior Director, Commercial Options since October 2012. Mr. Lawson joined us from Ventana, where he worked for nearly 15 years and served in a variety of roles with increasing responsibility in the North American commercial organization. He also served in the United States Air Force for nearly 10 years between Active and Reserve Duty as a certified Histology Technician.
        • Stephen A. Barat, PhD.

          Senior Vice President of Therapeutics
          Dr. Barat has served as our Senior Vice President of Therapeutics since October 2021. Prior to joining us, Dr. Barat was the U.S. Head, Non-clinical Safety Leaders in Non-clinical Safety Assessment at Janssen, where he led a large team that supported programs in all phases of discovery and development, from target assessment and lead optimization through candidate selection, early/late-stage development and registration. Before Janssen, he served as Vice President, Preclinical Research and Early Development at Scynexis and held additional senior roles at Allergan (Actavis/Forest Laboratories) and Schering-Plough/Merck. During his career, Dr. Barat has contributed to the development and registration of 15 new drug products, earned international recognition as a speaker and continuing education faculty on drug development topics, and has been an active member of  industry working groups with USP and PQRI.  A graduate of Rutgers University, Dr. Barat earned his Ph.D. in biomedical sciences, pharmacology and toxicology from the University of Medicine and Dentistry - New Jersey Medical School. 
          • Laura L. Godlewski

            Senior Vice President of Finance and Administration
            Ms. Godlewski has served as our Senior Vice President of Finance and Administration since February 2022. Since January 2015, she served as our Vice President of Accounting and Financial Reporting and previously as our Corporate Controller. Prior to joining the Company, Ms. Godlewski was Human Services Division Director of Finance at Providence Service Corporation, a publicly traded behavioral health company, where she held various roles of increasing responsibility including Corporate Director of Finance and Accounting and Division Controller from 2008 to 2014. In her early career, Ms. Godlewski was an Audit Manager with KPMG LLP where she conducted audits for clients across several industries including manufacturing, information technology and financial services. Ms. Godlewski received her B.A. in Accounting from Michigan State University and is a certified public accountant in the State of Michigan.